Having established that intranasal insulin/L-penetratin administration was effective at mild stage of cognitive dysfunction but not at severe cognitive dysfunction in senescence-accelerated mice (Kamei et al., 2018), this group investigated the effectiveness of GLP-1 receptor agonist, exendin-4, in modulating severe cognitive impairment. This evidence concerns the gene INS and Cognitive impairment.